The state of lung cancer research: A global analysis

Journal of Thoracic Oncology

Volumn 11, Issue 7, 2016, Pages 1040-1050

  Aggarwal, Ajay ^a   Lewison, Grant ^a,b   Idir, Saliha ^c   Peters, Matthew ^d   Aldige, Carolyn ^e   Boerckel, Win ^f   Boyle, Peter ^g   Trimble, Edward L ^h   Roe, Philip ^b   Sethi, Tariq ⁱ   Fox, Jesme ^j   Sullivan, Richard ^a  

^a GUY S HOSPITAL   (United Kingdom)

^b Evaluametrics Ltd   (United Kingdom)

^c MACQUARIE UNIVERSITY   (Australia)

^d PFIZER INC   (United States)

^e Prevent Cancer Foundation   (United States)

^f CancerCare   (United States)

^g INTERNATIONAL PREVENTION RESEARCH INSTITUTE   (France)

^h NATIONAL CANCER INSTITUTE   (United States)

ⁱ KING'S COLLEGE LONDON   (United Kingdom)

^j The Roy Castle Lung Cancer Foundation   (United Kingdom)

more..

Author keywords

Bibliometrics; Health policy; Lung cancer; Research

Indexed keywords

ARTICLE; BASIC RESEARCH; BIBLIOMETRICS; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER RESEARCH; HEALTH CARE POLICY; HUMAN; LUNG CANCER; PRIORITY JOURNAL; QUALITY OF LIFE; SMOKING; SYSTEMATIC REVIEW; SYSTEMIC THERAPY; TRANSLATIONAL RESEARCH; CHINA; INTERNATIONAL COOPERATION; LUNG NEOPLASMS; MEDICAL RESEARCH;

BIBLIOMETRICS; BIOMEDICAL RESEARCH; CHINA; HUMANS; INTERNATIONAL COOPERATION; LUNG NEOPLASMS;

EID: 84978264042     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2016.03.010     Document Type: Article

References (48)

1. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Dicker D, et al. The global burden of cancer 2013. JAMA Oncol. 2015;1:505-527.
2. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359-E386.
3. Luengo-Fernandez R, Leal J, Gray A, Sullivan R. Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol. 2013;14: 1165-1174.
4. Collin J. Tobacco control, global health policy and development: towards policy coherence in global governance. Tob Control. 2012;21:274-280.
5. Jha P, Peto R. Global effects of smoking, of quitting, and of taxing tobacco. N Engl J Med. 2014;370:60-68.
6. De Angelis R, Sant M, Coleman MP, et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5 - a population-based study. Lancet Oncol. 2014;15:23-34.
7. American Cancer Society. Global Cancer Facts & Figures 2009. Atlanta, GA: American Cancer Society; 2009.
8. Morgensztern D, Ng SH, Gao F, Govindan R. Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey. J Thorac Oncol. 2010;5:29-33.
9. Halpern MT, Ward EM, Pavluck AL, Schrag NM, Bian J, Chen AY. Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: a retrospective analysis. Lancet Oncol. 2008;9:222-223.
10. Berglund A, Holmberg L, Tishelman C, Wagenius G, Eaker S, Lambe M. Social inequalities in non-small cell lung cancer management and survival: a populationbased study in central Sweden. Thorax. 2010;65:327-333.
11. Navani N, Nankivell M, Lawrence DR, et al. Lung cancer diagnosis and stagingwith endobronchial ultrasound-guided transbronchial needle aspiration compared with conventional approaches: an open-label, pragmatic, randomised controlled trial. Lancet Respir Med. 2015;3:282-289.
12. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-smallcell lung cancer. N Engl J Med. 2002;346:92-98.
13. Eckhouse S, Lewison G, Sullivan R. Trends in the global funding and activity of cancer research. Mol Oncol. 2008;2:20-32.
14. Chalkidou K, Marquez P, Dhillon PK, et al. Evidenceinformed frameworks for cost-effective cancer care and prevention in low, middle, and high-income countries. Lancet Oncol. 2014;15:e119-e131.
15. Derrick GE, Pavone V. Democratising research evaluation: achieving greater public engagement with bibliometrics-informed peer review. Science and Public Policy. 2013;40:563-575.
16. Hood W, Wilson C. The literature of bibliometrics, scientometrics, and informetrics. Scientometrics. 2001;52: 291-314.
17. Lewison G. The definition of biomedical research subfields with title keywords and application to the analysis of research outputs. Research Evaluation. 1996;6:25-36.
18. Waltman L, van Eck NJ. Field-normalized citation impact indicators and the choice of an appropriate counting method. 2015. arXiv preprint arXiv:150104431.
19. Huffman MD, Baldridge A, Bloomfield GS, et al. Global cardiovascular research output, citations, and collaborations: a time-trend, bibliometric analysis (1999-2008). PloS One. 2013;8:e83440.
20. Lewison G, Paraje G. The classification of biomedical journals by research level. Scientometrics. 2004;60: 145-157.
21. Aggarwal A, Batura R, Sullivan R. The media and cancer: education or entertainment? An ethnographic study of European cancer journalists. Ecancermedicalscience. 2014;8:423.
22. Slater MD, Long M, Bettinghaus EP, Reineke JB. News coverage of cancer in the United States: a national sample of newspapers, television, and magazines. J Health Commun. 2008;13:523-537.
23. Konfortion J, Jack RH, Davies EA. Coverage of common cancer types in UK national newspapers: a content analysis. BMJ Open. 2014;4:e004677.
24. Williamson JML, Jones IH, Hocken DB. How does the media profile of cancer compare with prevalence? Ann R Coll Surg Engl. 2011;93:9-12.
25. Lewison G, Tootell S, Roe P, Sullivan R. How do the media report cancer research? A study of the UK's BBC website. Br J Cancer. 2008;99:569-576.
26. Len-Rios ME, Park S, Cameron GT, Duke DL, Kreuter M. Study asks if reporter's gender or audience predict for paper's cancer coverage. Newspaper Research Journal. 2008;29:91.
27. Saving Lives through Research: Annual Report and Accounts 2012/2013. London, United Kingdom: Cancer Research UK; 2014.
28. A snapshot of lung cancer. National Cancer Institute website. http://www.cancer.gov/research/progress/snapshots/lung. Posted November 5, 2014. Accessed September 14, 2015.
29. She J, Yang P, Hong Q, Bai C. Lung cancer in China: challenges and interventions. Chest. 2013;143:1117-1126.
30. Lin H-H, Murray M, Cohen T, Colijn C, Ezzati M. Effects of smoking and solid-fuel use on COPD, lung cancer, and tuberculosis in China: a time-based, multiple risk factor, modelling study. Lancet. 2008;372:1473-1483.
31. Chen W, Zheng R, Zeng H, Zhang S. Epidemiology of lung cancer in China. Thorac Cancer. 2015;6:209-215.
32. Torring ML, Frydenberg M, Hansen RP, Olesen F, Vedsted P. Evidence of increasing mortality with longer diagnostic intervals for five common cancers: a cohort study in primary care. Eur J Cancer. 2013;49:2187-2198.
33. Walters S, Maringe C, Coleman MP, et al. Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a populationbased study, 2004-2007. Thorax. 2013;68:551-564.
34. O'Dowd EL, McKeever TM, Baldwin DR, et al. What characteristics of primary care and patients are associated with early death in patients with lung cancer in the UK? Thorax. 2015;70:161-168.
35. Field JK, Oudkerk M, Pedersen JH, Duffy SW. Prospects for population screening and diagnosis of lung cancer. Lancet. 2013;382:732-741.
36. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363:733-742.
37. Mack JW, Weeks JC, Wright AA, Block SD, Prigerson HG. End-of-life discussions, goal attainment, and distress at the end of life: predictors and outcomes of receipt of care consistent with preferences. J Clin Oncol. 2010;28:1203-1208.
38. Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16:187-199.
39. Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009;374:379-386.
40. Shaw AT, Kim D-W, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368:2385-2394.
41. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123-135.
42. Louie AV, Palma DA, Dahele M, Rodrigues GB, Senan S. Management of early-stage non-small cell lung cancer using stereotactic ablative radiotherapy: controversies, insights, and changing horizons. Radiother Oncol. 2015;114:138-147.
43. Provencio M, Sanchez A, Garrido P, Valcarcel F. New molecular targeted therapies integrated with radiation therapy in lung cancer. Clin Lung Cancer. 2010;11:91-97.
44. Begg AC, Stewart FA, Vens C. Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer. 2011;11:239-253.
45. Eckhouse S, Lewison G, Sullivan R. Trends in the global funding and activity of cancer research. Mol Oncol. 2008;2:20-32.
46. Hawkes N. UK must improve its recruitment rate in clinical trials, report says. BMJ. 2012;345:e8104.
47. Collier R. Rapidly rising clinical trial costs worry researchers. CMAJ. 2009;180:277-278.
48. Jones CW, Handler L, Crowell KE, Keil LG, Weaver MA, Platts-Mills TF. Non-publication of large randomized clinical trials: cross sectional analysis. BMJ. 2013;347:f6104.